

Special Issue

CAR-T Cell Therapy in Hematological Malignancies

Message from the Guest Editor

Chimeric Antigen Receptor T-cell (CAR-T) therapy has yielded significant success in treating hematological malignancies, marking a transformative advancement in B-lineage malignancies. The key focus to advance CAR-T cell therapy in B-lineage-derived cancers lies in improving the product quality, duration of engraftment and combinatorial targeting as well as the incorporation of complementary therapies to successfully treat patients with CD19- and BCMA antigen loss. These strategies aim to address challenges such as antigen escape and tumor heterogeneity, which contribute to treatment resistance. Novel technological innovations are required to refine the effectiveness of CAR-T cells, potentially overcoming the main reasons for CAR treatment failure. Ongoing efforts are directed towards strategies and technologies that can overcome these limitations and pave the way for its broader and more potent application in the realm of cancer therapeutics. In this Special Issue, we aim to showcase new advancements in CAR-T cell therapy for the treatment of hematological cancers, and especially want to highlight translational work in lymphoid and myeloid diseases.

Guest Editor

Prof. Dr. Patrick Schlegel

Faculty of Medicine and Health, University of Sydney, Sydney, Australia

Deadline for manuscript submissions

closed (31 July 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/196240

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).